PT - JOURNAL ARTICLE AU - Ropri, Ali S. AU - Lam, Tiffany G. AU - Kalia, Vrinda AU - Buchanan, Heather M. AU - Bartosch, Anne Marie W. AU - Youth, Elliot H. H. AU - Xiao, Harrison AU - Ross, Sophie K. AU - Jain, Anu AU - Chakrabarty, Jayanta K. AU - Kang, Min Suk AU - Boyett, Deborah AU - Spinazzi, Eleonora F. AU - Iodice, Gail AU - McGovern, Robert A. AU - Honig, Lawrence S. AU - Brown, Lewis M. AU - Miller, Gary W. AU - McKhann, Guy M. AU - Teich, Andrew F. TI - Alzheimer’s disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression AID - 10.1101/2024.06.11.24308706 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.11.24308706 4099 - http://medrxiv.org/content/early/2024/06/13/2024.06.11.24308706.short 4100 - http://medrxiv.org/content/early/2024/06/13/2024.06.11.24308706.full AB - INTRODUCTION Normal pressure hydrocephalus (NPH) patients undergoing cortical shunting frequently show early AD pathology on cortical biopsy, which is predictive of progression to clinical AD. The objective of this study was to use samples from this cohort to identify CSF biomarkers for AD-related CNS pathophysiologic changes using tissue and fluids with early pathology, free of post-mortem artifact.METHODS We analyzed Simoa, proteomic, and metabolomic CSF data from 81 patients with previously documented pathologic and transcriptomic changes.RESULTS AD pathology on biopsy correlates with CSF β-amyloid-40/42, neurofilament light chain (NfL), and phospho-tau-181(p-tau181)/β-amyloid-42, while several gene expression modules correlate with NfL. Proteomic analysis highlights 7 core proteins that correlate with pathology and gene expression changes on biopsy, and metabolomic analysis of CSF identifies disease-relevant groups that correlate with biopsy data..DISCUSSION As additional biomarkers are added to AD diagnostic panels, our work provides insight into the CNS pathophysiology these markers are tracking.Competing Interest StatementLSH reports grants from NIH, New York State Dept of Health, Lewy Body Disease Association, CurePSP, Abbvie, Acumen, Alector, Biogen, Bristol-Myer Squibb, Cognition, EIP, Eisai, Genentech/Roche, Janssen/Johnson and Johnson, Transposon Therapeutics, UCB, and Vaccinex, as well as consulting fees from Biogen, Corium, Eisai, Genentech/Roche, and New Amsterdam, Payment or honoraria from Eisai Pharmaceuticals, Medscape, and Biogen, Payment for expert testimony from Monsanto and legal firms, support for attending meetings and/or travel from Eisai Pharmaceuticals, participation on a data safety monitoring or advisory board from Prevail Therapeutics/Lilly, Cortexyme, and Eisai, and a leadership role in the Alzheimer's Association. GWM reports grant funding from NIH, CancerUK, Department of Defense (USAMRAA), Alley Corp, and SPARK-NS. AFT reports grant funding from NIH and Regeneron, stock ownership in Biogen and Ionis, paid committee work for DOD and NIH, and unpaid committee work for the Alzheimer's Association. RAM reports grants from NIH, Minnesota Partnership for Biotechnology and Genomics, Minnesota Robotics Institute, and MnDRIVE Data Science Initiative. GMM reports grants from NIH, consulting with Koh Young Inc and NeuroOne Technologies, participation on the Medronic SLATE trial Publication Committee, and leadership/committee roles in the Neurosurgical Society of America, AANS, and ASSFN. LMB reports support from NIH. The other authors have nothing to report.Funding StatementThis study was supported by NIH grants K08-AG049938 (AFT), K76-AG054868 (AFT), R01-AG073360 (AFT/GMM), and P30-AG066462 (Small), and with support from the Thompson Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Columbia University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study is available upon reasonable request to the authors.ADAlzheimer’s diseaseNPHNormal pressure hydrocephalus